Ex-Allscripts accountant charged with insider trading; Hospital CIOs to be more selective about travel;

News From Around the Web

> A former Allscripts accountant has been charged with insider trading, according to the Chicago Tribune. Federal prosecutors allege that trades by Steven M. Dombrowski resulted in a $286,000 profit. Article

> Hospital CIOs are going to be more selective about travel in 2014, according to new healthsystemCIO.com survey. "For an increasing number of CIOs, the "must-attend" list no longer includes HIMSS," an accompanying article states. "In the survey, 51 percent said they plan to attend the show, compared to 59 percent last year." Article

Health Insurance News 

> The "three Rs" of the Affordable Care Act help insurers manage the financial risk of covering everyone, while keeping premiums reasonable, Kaiser Health News reported. With less freedom to set rates, insurers can use the three Rs--risk corridors, reinsurance and risk adjustment--to maintain order as sick, previously uninsured consumers enter the market. But Republican debt ceiling negotiations next month may eliminate them. Article

> The single-payer system has found champions in oncologists, who have a "moral and ethical obligation" to endorse a universal healthcare system financed by a single payer. Article

EMR News

> The Centers for Medicare & Medicaid Services has published inconsistent information about how often providers need to demonstrate Meaningful Use, which may be confusing many providers about whether they must successfully attest every year in order to participate in the program, according to attorney Kathie McClure, with Wyatt, Tarrant & Combs in Louisville, Ky. Article

And Finally... This proves it, Jennifer Lawrence really is just like the rest of us. Article

Suggested Articles

The potential long-term impacts of COVID-19 on how Medicare Advantage's star ratings are calculated remain unclear, experts say.

There is a potential legal skirmish brewing between two of the largest telehealth companies over patent claims.

Buoyed by strong demand for its stock, GoodRx raised $1.1 billion in its IPO after pricing its deal well above its expected price range.